VLRLClinical•businesswire•
Valar Labs’ CHAI Biomarkers Validated in New Study in European Urology for Predicting Outcomes of High Grade Ta Bladder Cancer
Sentiment:Positive (80)
Summary
PALO ALTO, Calif.--(BUSINESS WIRE)--Valar Labs publishes new evidence in European Urology validating CHAI biomarkers for risk stratification of recurrence and progression
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on June 13, 2025 by businesswire